603392 万泰生物
已收盘 12-05 15:00:00
资讯
新帖
简况
万泰生物（603392）披露取消监事会并修订公司章程议案获股东会通过，11月28日股价下跌2.18%
证券之星 · 11-28
万泰生物（603392）披露取消监事会并修订公司章程议案获股东会通过，11月28日股价下跌2.18%
每周股票复盘：万泰生物（603392）拟取消监事会并修订多项制度
证券之星 · 11-23
每周股票复盘：万泰生物（603392）拟取消监事会并修订多项制度
11月20日万泰生物现2920.56万元大宗交易
证券之星 · 11-20
11月20日万泰生物现2920.56万元大宗交易
每周股票复盘：万泰生物（603392）拟取消监事会并修订公司章程
证券之星 · 11-16
每周股票复盘：万泰生物（603392）拟取消监事会并修订公司章程
万泰生物（603392）披露拟取消监事会并修订公司章程，11月12日股价下跌0.65%
证券之星 · 11-12
万泰生物（603392）披露拟取消监事会并修订公司章程，11月12日股价下跌0.65%
万泰生物：公司日常通过投资者热线、策略会、E互动、业绩说明会等多种方式与资本市场沟通
证券日报 · 11-05
万泰生物：公司日常通过投资者热线、策略会、E互动、业绩说明会等多种方式与资本市场沟通
每周股票复盘：万泰生物（603392）Q3营收增12.5%，净利下滑576.34%
证券之星 · 11-02
每周股票复盘：万泰生物（603392）Q3营收增12.5%，净利下滑576.34%
万泰生物公布国际专利申请：“一种生物体样本快速检测装置”
证券之星 · 11-01
万泰生物公布国际专利申请：“一种生物体样本快速检测装置”
万泰生物(603392)9月30日股东户数4.2万户，较上期增加9.41%
证券之星 · 10-30
万泰生物(603392)9月30日股东户数4.2万户，较上期增加9.41%
图解万泰生物三季报：第三季度单季净利润同比下降576.34%
证券之星 · 10-29
图解万泰生物三季报：第三季度单季净利润同比下降576.34%
每周股票复盘：万泰生物（603392）拟注销72.997万股回购股份
证券之星 · 10-26
每周股票复盘：万泰生物（603392）拟注销72.997万股回购股份
每周股票复盘：万泰生物（603392）拟注销729,970股回购股份
证券之星 · 10-19
每周股票复盘：万泰生物（603392）拟注销729,970股回购股份
万泰生物（603392）披露变更部分回购股份用途并注销的公告，10月15日股价上涨0.09%
证券之星 · 10-15
万泰生物（603392）披露变更部分回购股份用途并注销的公告，10月15日股价上涨0.09%
研究发现：国产二价HPV疫苗“馨可宁” 十年保护力优异
格隆汇 · 08-24
研究发现：国产二价HPV疫苗“馨可宁” 十年保护力优异
上半年净利暴跌155% 万泰生物业绩“变脸”
市场资讯 · 08-22
上半年净利暴跌155% 万泰生物业绩“变脸”
万泰生物(603392.SH)：九价人乳头瘤病毒疫苗(大肠埃希菌)首次获得批签发证明
智通财经 · 08-21
万泰生物(603392.SH)：九价人乳头瘤病毒疫苗(大肠埃希菌)首次获得批签发证明
万泰生物(603392.SH)发布上半年业绩，由盈转亏至1.44亿元
智通财经 · 08-20
万泰生物(603392.SH)发布上半年业绩，由盈转亏至1.44亿元
万泰生物：公司九价HPV疫苗通过国家药监局审评和GMP检查
证券之星 · 08-12
万泰生物：公司九价HPV疫苗通过国家药监局审评和GMP检查
万泰生物：公司将全力以赴做好研发和经营工作
证券之星 · 08-12
万泰生物：公司将全力以赴做好研发和经营工作
生物制品行业盘中跳水，成大生物跌0.35%
市场透视 · 08-12
生物制品行业盘中跳水，成大生物跌0.35%
加载更多
公司概况
公司名称：
北京万泰生物药业股份有限公司
所属行业：
医药制造业
上市日期：
2020-04-29
主营业务：
北京万泰生物药业股份有限公司的主营业务是诊断试剂、疫苗以及医疗器械的研发、生产和销售。公司的主要产品是体外诊断试剂、诊断仪器、重组戊型肝炎疫苗、二价HPV疫苗、鼻喷流感病毒载体新冠肺炎疫苗、九价HPV疫苗。
发行价格：
8.75
{"stockData":{"symbol":"603392","market":"SH","secType":"STK","nameCN":"万泰生物","latestPrice":46.69,"timestamp":1764918000000,"preClose":46.52,"halted":0,"volume":3001993,"delay":0,"changeRate":0.0037,"floatShares":1265000000,"shares":1265000000,"eps":-0.2639,"marketStatus":"已收盘","change":0.17,"latestTime":"12-05 15:00:00","open":46.5,"high":46.75,"low":45.69,"amount":139000000,"amplitude":0.0228,"askPrice":46.7,"askSize":177,"bidPrice":46.69,"bidSize":111,"shortable":0,"etf":0,"ttmEps":-0.2639,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"adjPreClose":46.52,"symbolType":"stock","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":51.17,"lowLimit":41.87,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1265122774,"isCdr":false,"pbRate":4.89,"roa":"--","roe":"--","epsLYR":0.08,"committee":0.105325,"marketValue":59069000000,"turnoverRate":0.0024,"status":0,"floatMarketCap":59069000000},"requestUrl":"/m/hq/s/603392","defaultTab":"news","newsList":[{"id":"2586738435","title":"万泰生物（603392）披露取消监事会并修订公司章程议案获股东会通过，11月28日股价下跌2.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586738435","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586738435?lang=zh_cn&edition=full","pubTime":"2025-11-28 22:14","pubTimestamp":1764339272,"startTime":"0","endTime":"0","summary":"截至2025年11月28日收盘，万泰生物报收于48.02元，较前一交易日下跌2.18%，最新总市值为607.51亿元。该股当日开盘49.19元，最高49.21元，最低47.96元，成交额达2.78亿元，换手率为0.46%。所有议案均获通过，无否决议案。表决结果合法有效，律师出具了见证意见。出席股东代表有表决权股份总数占公司总股本的78.6148%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800039722.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1589","09633","LU1981816686.USD","603392","BK0239","BK1200"],"gpt_icon":0},{"id":"2585103680","title":"每周股票复盘：万泰生物（603392）拟取消监事会并修订多项制度","url":"https://stock-news.laohu8.com/highlight/detail?id=2585103680","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585103680?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:24","pubTimestamp":1763835852,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，万泰生物报收于51.68元，较上周的54.89元下跌5.85%。本周，万泰生物11月17日盘中最高价报55.08元。11月21日盘中最低价报51.4元，股价触及近一年最低点。万泰生物当前最新总市值653.82亿元，在生物制品板块市值排名1/51，在两市A股市值排名251/5167。本周关注点来自交易信息汇总：11月20日万泰生物发生2920.56万元大宗交易。来自公司公告汇总：万泰生物拟取消监事会，由审计委员会行使监事会职权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","BK1200","09633","BK0239","BK1589","LU1981816686.USD"],"gpt_icon":0},{"id":"2584187814","title":"11月20日万泰生物现2920.56万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2584187814","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584187814?lang=zh_cn&edition=full","pubTime":"2025-11-20 17:49","pubTimestamp":1763632152,"startTime":"0","endTime":"0","summary":"证券之星消息，11月20日万泰生物发生大宗交易，交易数据如下：近三个月该股共发生3笔大宗交易，合计成交5160.0手，溢价成交3笔。该股近期无解禁股上市。截至2025年11月20日收盘，万泰生物(603392)报收于53.37元，下跌0.52%，换手率0.15%，成交量1.86万手，成交额9982.48万元。该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000027039.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","09633","BK1589","BK1200","LU1981816686.USD","603392"],"gpt_icon":0},{"id":"2583651665","title":"每周股票复盘：万泰生物（603392）拟取消监事会并修订公司章程","url":"https://stock-news.laohu8.com/highlight/detail?id=2583651665","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583651665?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:29","pubTimestamp":1763234951,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，万泰生物报收于54.89元，较上周的55.11元下跌0.4%。本周关注点公司公告汇总：万泰生物拟取消监事会，其职能由董事会审计委员会行使。公司公告汇总北京万泰生物药业股份有限公司于2025年11月12日召开第六届董事会第十二次会议和第六届监事会第十二次会议，审议通过《关于取消监事会并修订<公司章程>的议案》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1589","LU1981816686.USD","09633","603392","BK1200","BK0239"],"gpt_icon":0},{"id":"2582701593","title":"万泰生物（603392）披露拟取消监事会并修订公司章程，11月12日股价下跌0.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582701593","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582701593?lang=zh_cn&edition=full","pubTime":"2025-11-12 22:50","pubTimestamp":1762959029,"startTime":"0","endTime":"0","summary":"截至2025年11月12日收盘，万泰生物报收于55.12元，较前一交易日下跌0.65%，最新总市值为697.34亿元。近日，万泰生物发布关于召开2025年第二次临时股东会的通知。本次会议审议的议案包括取消监事会并修订《公司章程》、修订多项公司治理制度，以及选举吕赟先生为第六届董事会非独立董事等事项。其中，取消监事会并修订《公司章程》等三项议案为特别决议议案，第7.01项议案对中小投资者单独计票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200041740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1589","LU1981816686.USD","09633","603392","BK1200","BK0239"],"gpt_icon":0},{"id":"2581279457","title":"万泰生物：公司日常通过投资者热线、策略会、E互动、业绩说明会等多种方式与资本市场沟通","url":"https://stock-news.laohu8.com/highlight/detail?id=2581279457","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581279457?lang=zh_cn&edition=full","pubTime":"2025-11-05 20:33","pubTimestamp":1762345980,"startTime":"0","endTime":"0","summary":"证券日报网讯万泰生物11月5日在互动平台回答投资者提问时表示，公司日常通过投资者热线、策略会、E互动、业绩说明会等多种方式与资本市场沟通。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-05/doc-infwkiir4241075.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-05/doc-infwkiir4241075.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603392","BK1200","LU1981816686.USD","BK1589","09633","BK0239"],"gpt_icon":0},{"id":"2580476036","title":"每周股票复盘：万泰生物（603392）Q3营收增12.5%，净利下滑576.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580476036","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580476036?lang=zh_cn&edition=full","pubTime":"2025-11-02 04:08","pubTimestamp":1762027695,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，万泰生物报收于56.37元，较上周的54.7元上涨3.05%。本周，万泰生物10月31日盘中最高价报58.66元。业绩披露要点2025年前三季度，万泰生物主营收入14.98亿元，同比下降23.09%；归母净利润-1.73亿元，同比下降165.04%；扣非净利润-3.08亿元，同比下降850.36%。毛利率为53.58%，负债率14.6%。公司公告汇总万泰生物2025年第三季度报告显示，利润总额本报告期同比下降138.31%，主因疫苗与IVD板块受市场调整及集采影响，收入与毛利率回落。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000742.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","09633"],"gpt_icon":0},{"id":"2580414615","title":"万泰生物公布国际专利申请：“一种生物体样本快速检测装置”","url":"https://stock-news.laohu8.com/highlight/detail?id=2580414615","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580414615?lang=zh_cn&edition=full","pubTime":"2025-11-01 05:49","pubTimestamp":1761947381,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示万泰生物（603392）公布了一项国际专利申请，专利名为“一种生物体样本快速检测装置”，专利申请号为PCT/CN2025/081869，国际公布日为2025年10月30日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来万泰生物已公布的国际专利申请4个，较去年同期增加了300%。结合公司2025年中报财务数据，今年上半年公司在研发方面投入了2.76亿元，同比减42.39%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110100004797.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1200","BK1589","LU1981816686.USD","09633","603392"],"gpt_icon":0},{"id":"2579835118","title":"万泰生物(603392)9月30日股东户数4.2万户，较上期增加9.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579835118","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579835118?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:22","pubTimestamp":1761816130,"startTime":"0","endTime":"0","summary":"证券之星消息，近日万泰生物披露，截至2025年9月30日公司股东户数为4.2万户，较6月30日增加3611.0户，增幅为9.41%。在生物制品行业个股中，万泰生物股东户数高于行业平均水平，截至9月30日，生物制品行业平均股东户数为3.41万户。从股价来看，2025年6月30日至2025年9月30日，万泰生物区间跌幅为7.3%，在此期间股东户数增加3611.0户，增幅为9.41%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000032691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1589","603392","09633","LU1981816686.USD","BK1200"],"gpt_icon":0},{"id":"2579031949","title":"图解万泰生物三季报：第三季度单季净利润同比下降576.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579031949","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579031949?lang=zh_cn&edition=full","pubTime":"2025-10-29 20:18","pubTimestamp":1761740293,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物2025年三季报显示，前三季度公司主营收入14.98亿元，同比下降23.09%；归母净利润-1.73亿元，同比下降165.04%；扣非净利润-3.08亿元，同比下降850.36%；其中2025年第三季度，公司单季度主营收入6.55亿元，同比上升12.5%；单季度归母净利润-2938.38万元，同比下降576.34%；单季度扣非净利润-6501.29万元，同比下降188.63%；负债率14.6%，投资收益6651.1万元，财务费用-1134.23万元，毛利率53.58%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900041421.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","09633"],"gpt_icon":0},{"id":"2578501789","title":"每周股票复盘：万泰生物（603392）拟注销72.997万股回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2578501789","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578501789?lang=zh_cn&edition=full","pubTime":"2025-10-26 01:55","pubTimestamp":1761414910,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，万泰生物报收于54.7元，较上周的55.08元下跌0.69%。本周，万泰生物10月20日盘中最高价报55.67元。本周关注点公司公告汇总：万泰生物拟将729,970股回购股份变更为注销并减少注册资本。公司公告汇总北京万泰生物药业股份有限公司拟将回购专用证券账户中尚未使用的729,970股股份用途由“用于员工持股计划或股权激励”变更为“用于注销并减少注册资本”。本次注销后，公司总股本将由1,265,122,774股减少至1,264,392,804股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600000342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","09633","BK1589","BK1200","LU1981816686.USD","603392"],"gpt_icon":0},{"id":"2576049369","title":"每周股票复盘：万泰生物（603392）拟注销729,970股回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2576049369","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576049369?lang=zh_cn&edition=full","pubTime":"2025-10-19 03:13","pubTimestamp":1760814788,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，万泰生物报收于55.08元，较上周的57.56元下跌4.31%。本周，万泰生物10月13日盘中最高价报57.75元。本周关注点公司公告汇总：万泰生物拟将729,970股回购股份用途变更为注销并减少注册资本。万泰生物公告显示，拟注销的729,970股占公司当前总股本的0.0577%，来源于2022年12月21日完成的股份回购。截至公告日，剩余729,970股尚未使用。本次注销后，公司总股本将由1,265,122,774股减少至1,264,392,804股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900000618.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1200","BK1589","09633","BK0239","603392","LU1981816686.USD"],"gpt_icon":0},{"id":"2575366587","title":"万泰生物（603392）披露变更部分回购股份用途并注销的公告，10月15日股价上涨0.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575366587","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575366587?lang=zh_cn&edition=full","pubTime":"2025-10-15 22:38","pubTimestamp":1760539091,"startTime":"0","endTime":"0","summary":"近日，万泰生物发布《关于变更部分回购股份用途并注销的公告》。公告称，公司拟将回购专用证券账户中已回购但尚未使用的729,970股股份用途由“用于员工持股计划或股权激励”变更为“用于注销并减少注册资本”，占公司当前总股本的0.0577%。公司于2022年12月21日完成股份回购，累计回购1,585,320股，其中855,350股已用于2023年员工持股计划，后因计划终止而不再使用。本次注销后，公司总股本将由1,265,122,774股减少至1,264,392,804股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101500038426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","BK1200","603392","BK0239","BK1589","LU1981816686.USD"],"gpt_icon":0},{"id":"2561256922","title":"研究发现：国产二价HPV疫苗“馨可宁” 十年保护力优异","url":"https://stock-news.laohu8.com/highlight/detail?id=2561256922","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561256922?lang=zh_cn&edition=full","pubTime":"2025-08-24 08:51","pubTimestamp":1755996691,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1200","09633","BK0239","159646","LU1981816686.USD","BK1589","603392"],"gpt_icon":0},{"id":"2561141475","title":"上半年净利暴跌155% 万泰生物业绩“变脸”","url":"https://stock-news.laohu8.com/highlight/detail?id=2561141475","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561141475?lang=zh_cn&edition=full","pubTime":"2025-08-22 00:26","pubTimestamp":1755793560,"startTime":"0","endTime":"0","summary":" 万泰生物交出了自上市以来首份亏损的中报。8月20日晚，万泰生物公告披露，2025年上半年，万泰生物营收与净利润双双大幅下滑，其中净利润亏损达1.44亿元，同比骤降155.3%，扣非后净利润降幅更是高达481.93%。尽管其九价HPV疫苗已于今年6月上市，但市场反馈尚未达到预期，且生产成本持续攀升，对万泰生物的利润构成较大压力。同时，随着国内HPV疫苗市场众多竞争对手的加入，万泰生物的市场占有率面临被蚕食的风险。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-08-22/doc-infmupar9093755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1589","BK0239","BK1200","603392","LU1981816686.USD","09633"],"gpt_icon":0},{"id":"2561545475","title":"万泰生物(603392.SH)：九价人乳头瘤病毒疫苗(大肠埃希菌)首次获得批签发证明","url":"https://stock-news.laohu8.com/highlight/detail?id=2561545475","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561545475?lang=zh_cn&edition=full","pubTime":"2025-08-21 15:47","pubTimestamp":1755762469,"startTime":"0","endTime":"0","summary":"智通财经APP讯，万泰生物(603392.SH)发布公告，近日，公司全资子公司厦门万泰沧海生物技术有限公司生产的九价人乳头瘤病毒疫苗(大肠埃希菌)(以下简称“九价HPV疫苗”)获得中国食品药品检定研究院签发的《生物制品批签发证明》。公告称，随着九价HPV疫苗产品首次获得批签发证明，标志着公司的该产品正式投放市场，这将进一步丰富和优化公司的产品梯队，为公司形成新的收入和利润增长点，增强公司盈利能力和市场竞争能力，强化公司的市场地位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1332720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","603392","09633","LU1981816686.USD","BK1200","BK1589","159646"],"gpt_icon":0},{"id":"2560765931","title":"万泰生物(603392.SH)发布上半年业绩，由盈转亏至1.44亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2560765931","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560765931?lang=zh_cn&edition=full","pubTime":"2025-08-20 17:15","pubTimestamp":1755681331,"startTime":"0","endTime":"0","summary":"智通财经APP讯，万泰生物(603392.SH)发布2025年半年度报告，该公司营业收入为8.44亿元，同比减少38.25%。归属于上市公司股东的净亏损为1.44亿元。归属于上市公司股东的扣除非经常性损益的净亏损为2.43亿元。基本每股亏损为0.11元。营业收入下降，主要由于公司疫苗板块受市场调整、政府集采及九价HPV疫苗扩龄等影响，销售不及预期，疫苗板块收入较上年同期回落。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1332161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1200","BK1589","09633","BK0239","603392","LU1981816686.USD"],"gpt_icon":0},{"id":"2558261768","title":"万泰生物：公司九价HPV疫苗通过国家药监局审评和GMP检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2558261768","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558261768?lang=zh_cn&edition=full","pubTime":"2025-08-12 16:27","pubTimestamp":1754987249,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物08月12日在投资者关系平台上答复投资者关心的问题。公司所有产品的研发和生产过程严格遵循国家相关法规的规定，九价HPV疫苗通过了国家药品监督管理局的严格审评和注册核查，并通过了GMP符合性检查。公司将按照相关规定履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081200027162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0239","09633","BK1200","BK1589","603392","LU1981816686.USD"],"gpt_icon":0},{"id":"2558122716","title":"万泰生物：公司将全力以赴做好研发和经营工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2558122716","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558122716?lang=zh_cn&edition=full","pubTime":"2025-08-12 16:12","pubTimestamp":1754986367,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)08月12日在投资者关系平台上答复投资者关心的问题。投资者提问：你好！董秘:请问一下，贵公司作为疫苗龙头股，股价为何一直下跌不涨？投资者急需要情绪信心，请问公司如果化解？公司有考虑重组吗？万泰生物回复：您好！二级市场股价变动受诸多因素影响，公司将全力以赴做好研发和经营工作，持续加强与市场的沟通，提升自身长期内在价值。公司将按照相关规定履行信息披露义务。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081200026541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1589","LU1981816686.USD","603392","BK1200","09633","BK0239"],"gpt_icon":0},{"id":"2558455697","title":"生物制品行业盘中跳水，成大生物跌0.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558455697","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558455697?lang=zh_cn&edition=full","pubTime":"2025-08-12 10:40","pubTimestamp":1754966408,"startTime":"0","endTime":"0","summary":"08月12日，生物制品行业盘中跳水，截至10点40分，生物制品行业整体指数下跌1.01%，报6884.300点。从个股上来看，该行业的成分股中，成大生物跌0.35%，长春高新、万泰生物、上海莱士跌幅居前。从资金上来看，截止发稿，生物制品行业主力净流入为-3.27亿，其中西藏药业受到资金热捧，主力净流入2.03亿；拉长时间线来看，该板块近20日主力资金净流入-45.53亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081210400897420a71&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081210400897420a71&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600211","BK0239","603392","688739"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765140243461,"stockEarnings":[{"period":"1week","weight":-0.0277},{"period":"1month","weight":-0.1531},{"period":"3month","weight":-0.1849},{"period":"6month","weight":-0.3558},{"period":"1year","weight":-0.388},{"period":"ytd","weight":-0.3374}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0167},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.1529},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1644}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京万泰生物药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"41996人(较上一季度增加9.41%)","perCapita":"30124股","listingDate":"2020-04-29","address":"北京市昌平区科学园路31号","registeredCapital":"126512万元","survey":" 北京万泰生物药业股份有限公司的主营业务是诊断试剂、疫苗以及医疗器械的研发、生产和销售。公司的主要产品是体外诊断试剂、诊断仪器、重组戊型肝炎疫苗、二价HPV疫苗、鼻喷流感病毒载体新冠肺炎疫苗、九价HPV疫苗。","listedPrice":8.75},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万泰生物(603392)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万泰生物(603392)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万泰生物,603392,万泰生物股票,万泰生物股票老虎,万泰生物股票老虎国际,万泰生物行情,万泰生物股票行情,万泰生物股价,万泰生物股市,万泰生物股票价格,万泰生物股票交易,万泰生物股票购买,万泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万泰生物(603392)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万泰生物(603392)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}